Condition: Lupus Nephritis · Sponsor: NephroNet, Inc.
This is a Phase IV, open-label, randomized trial to determine whether the combination of Belimumab (BEL) and Voclosporin (VCS), plus background therapy with Mycophenolate Mofetil (MMF), improves the proportion of patients with proliferative lupus nephritis achieving complete renal response (CRR) compared to proportion of patients achieving CRR from recent clinical trials. This protocol will additionally determine whether combination therapy using Belimumab (BEL) and Voclosporin (VCS) facilitates rapid discontinuation of MMF.
This description comes directly from the study's public registry record.
Jeremy Whitson · 423-943-4265 · jwhitson@nephronet.com
Julie Scoggin · 804-467-3158 · jscoggin@nephronet.com
Always discuss trial participation with your own doctor first.
| AARA Clinical Research | Glendale, Arizona, United States | Recruiting |
| Piedmont Physicians Rheumatology | Atlanta, Georgia, United States | Recruiting |
| Georgia Nephrology Research Institute | Lawrenceville, Georgia, United States | Recruiting |
| Parris & Associates | Lawrenceville, Georgia, United States | Recruiting |
| Nephrology Clinical Trials Unit The Ohio State University Wexner Medical Center | Columbus, Ohio, United States | Recruiting |
| Oklahoma Medical Research Foundation | Oklahoma City, Oklahoma, United States | Recruiting |
| AARA Clinical Research | Fort Worth, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07225387